Skip to main content
PMC home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1995 Jun;48(6):548–552. doi: 10.1136/jcp.48.6.548

CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.

M Zandecki 1, T Facon 1, F Bernardi 1, V Izydorczyk 1, L Dupond 1, M François 1, R Reade 1, T Iaru 1, F Bauters 1, A Cosson 1
PMCID: PMC502686  PMID: 7545187

Abstract

AIMS--To determine whether a particular phenotype or antigen is preferentially related to monoclonal gammopathies of undetermined significance (MGUS). METHODS--Bone marrow specimens from 56 patients with MGUS were stained immunocytochemically (ABC peroxidase) for CD38, CD56, CD9, CD10, CD19, CD20, CD22, and MB2. Specimens from patients recently diagnosed with multiple myeloma and reactive bone marrow samples were studied in parallel. RESULTS--CD38 was expressed on all plasma cells from all MGUS samples tested, while 36% were positive for CD56, CD9 and MB2 were both expressed strongly; CD20 was moderately expressed, and staining for CD10 and CD22 was uncommon. For these five B cell antigens there was no clear difference between their expression in MGUS and in multiple myeloma. A great difference was found for CD19: in MGUS this antigen was expressed on 2-91% of plasma cells (mean 35%) and 77% patients had > 10% positive plasma cells; in multiple myeloma its expression was low and only 12% patients had > 10% positive plasma cells. When these results were converted to numbers of CD19 positive plasma cells per 100 nucleated bone marrow cells, reactive bone marrow and MGUS specimens had a similar number of positive plasma cells. There was no correlation between expression of any of the antigens tested. CONCLUSIONS--Many of the so-called pre-B, B or activation antigens are present on plasma cells from MGUS specimens, and expression of CD9, CD10, CD20, CD22, MB2, and CD38 in MGUS was very similar to that in multiple myeloma. CD56 was frequently expressed in MGUS. In this series CD19 was highly expressed in MGUS but not in multiple myeloma. Plasma cells bearing this antigen could represent the non-neoplastic process and determination of its expression could be useful for the diagnosis of MGUS.

Full text

PDF
548

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barker H. F., Hamilton M. S., Ball J., Drew M., Franklin I. M. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells. Br J Haematol. 1992 Jul;81(3):331–335. doi: 10.1111/j.1365-2141.1992.tb08236.x. [DOI] [PubMed] [Google Scholar]
  2. Barlogie B., Epstein J., Selvanayagam P., Alexanian R. Plasma cell myeloma--new biological insights and advances in therapy. Blood. 1989 Mar;73(4):865–879. [PubMed] [Google Scholar]
  3. Chan C. S., Wormsley S. B., Pierce L. E., Peter J. B., Schechter G. P. B-cell surface phenotypes of proliferating myeloma cells: target antigens for immunotherapy. Am J Hematol. 1990 Feb;33(2):101–109. doi: 10.1002/ajh.2830330206. [DOI] [PubMed] [Google Scholar]
  4. Dehou M. F., Schots R., Lacor P., Arras N., Verhavert P., Klöppel G., van Camp B. Diagnostic and prognostic value of the MB2 monoclonal antibody in paraffin-embedded bone marrow sections of patients with multiple myeloma and monoclonal gammopathy of undetermined significance. Am J Clin Pathol. 1990 Sep;94(3):287–291. doi: 10.1093/ajcp/94.3.287. [DOI] [PubMed] [Google Scholar]
  5. Drach J., Gattringer C., Huber H. Expression of the neural cell adhesion molecule (CD56) by human myeloma cells. Clin Exp Immunol. 1991 Mar;83(3):418–422. doi: 10.1111/j.1365-2249.1991.tb05654.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Duperray C., Klein B., Durie B. G., Zhang X., Jourdan M., Poncelet P., Favier F., Vincent C., Brochier J., Lenoir G. Phenotypic analysis of human myeloma cell lines. Blood. 1989 Feb;73(2):566–572. [PubMed] [Google Scholar]
  7. Durie B. G., Grogan T. M. CALLA-positive myeloma: an aggressive subtype with poor survival. Blood. 1985 Jul;66(1):229–232. [PubMed] [Google Scholar]
  8. Epstein J., Barlogie B., Katzmann J., Alexanian R. Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement. Blood. 1988 Apr;71(4):861–865. [PubMed] [Google Scholar]
  9. Epstein J., Xiao H. Q., He X. Y. Markers of multiple hematopoietic-cell lineages in multiple myeloma. N Engl J Med. 1990 Mar 8;322(10):664–668. doi: 10.1056/NEJM199003083221005. [DOI] [PubMed] [Google Scholar]
  10. Greipp P. R., Witzig T. E., Gonchoroff N. J., Habermann T. M., Katzmann J. A., O'Fallon W. M., Kyle R. A. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc. 1987 Nov;62(11):969–977. doi: 10.1016/s0025-6196(12)65066-6. [DOI] [PubMed] [Google Scholar]
  11. Grogan T. M., Durie B. G., Lomen C., Spier C., Wirt D. P., Nagle R., Wilson G. S., Richter L., Vela E., Maxey V. Delineation of a novel pre-B cell component in plasma cell myeloma: immunochemical, immunophenotypic, genotypic, cytologic, cell culture, and kinetic features. Blood. 1987 Oct;70(4):932–942. [PubMed] [Google Scholar]
  12. Grogan T. M., Durie B. G., Spier C. M., Richter L., Vela E. Myelomonocytic antigen positive multiple myeloma. Blood. 1989 Feb 15;73(3):763–769. [PubMed] [Google Scholar]
  13. HALLEN J. Frequency of "abnormal" serum globulins (M-components) in the aged. Acta Med Scand. 1963 Jun;173:737–744. [PubMed] [Google Scholar]
  14. Hall P. A., D'Ardenne A. J., Butler M. G., Habeshaw J. R., Stansfeld A. G. New marker of B lymphocytes, MB2: comparison with other lymphocyte subset markers active in conventionally processed tissue sections. J Clin Pathol. 1987 Feb;40(2):151–156. doi: 10.1136/jcp.40.2.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hamilton M. S., Ball J., Bromidge E., Franklin I. M. Surface antigen expression of human neoplastic plasma cells includes molecules associated with lymphocyte recirculation and adhesion. Br J Haematol. 1991 May;78(1):60–65. doi: 10.1111/j.1365-2141.1991.tb04383.x. [DOI] [PubMed] [Google Scholar]
  16. Harada H., Kawano M. M., Huang N., Harada Y., Iwato K., Tanabe O., Tanaka H., Sakai A., Asaoku H., Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993 May 15;81(10):2658–2663. [PubMed] [Google Scholar]
  17. Joshua D. E., Ioannidis R., Brown R., Francis S. E., Gibson J., Kronenberg H. Multiple myeloma: relationship between light chain isotype suppression, labelling index of plasma cells, and CD38 expression on peripheral blood lymphocytes. Am J Hematol. 1988 Sep;29(1):5–11. doi: 10.1002/ajh.2830290103. [DOI] [PubMed] [Google Scholar]
  18. King M. A., Nelson D. S. Tumor cell heterogeneity in multiple myeloma: antigenic, morphologic, and functional studies of cells from blood and bone marrow. Blood. 1989 May 15;73(7):1925–1935. [PubMed] [Google Scholar]
  19. Kiyokawa N., Kokai Y., Ishimoto K., Fujita H., Fujimoto J., Hata J. I. Characterization of the common acute lymphoblastic leukaemia antigen (CD10) as an activation molecule on mature human B cells. Clin Exp Immunol. 1990 Mar;79(3):322–327. doi: 10.1111/j.1365-2249.1990.tb08090.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Kyle R. A. "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. Mayo Clin Proc. 1993 Jan;68(1):26–36. doi: 10.1016/s0025-6196(12)60015-9. [DOI] [PubMed] [Google Scholar]
  21. Leo R., Boeker M., Peest D., Hein R., Bartl R., Gessner J. E., Selbach J., Wacker G., Deicher H. Multiparameter analyses of normal and malignant human plasma cells: CD38++, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann Hematol. 1992 Mar;64(3):132–139. doi: 10.1007/BF01697400. [DOI] [PubMed] [Google Scholar]
  22. Mayumi M., Kuritani T., Kubagawa H., Cooper M. D. IgG subclass expression by human B lymphocytes and plasma cells: B lymphocytes precommitted to IgG subclass can be preferentially induced by polyclonal mitogens with T cell help. J Immunol. 1983 Feb;130(2):671–677. [PubMed] [Google Scholar]
  23. Nathan P. D., Walker L., Hardie D., Richardson P., Khan M., Johnson G. D., Ling N. R. An antigenic study of human plasma cells in normal tissue and in myeloma: identification of a novel plasma cell associated antigen. Clin Exp Immunol. 1986 Jul;65(1):112–119. [PMC free article] [PubMed] [Google Scholar]
  24. Omedè P., Boccadoro M., Fusaro A., Gallone G., Pileri A. Multiple myeloma: 'early' plasma cell phenotype identifies patients with aggressive biological and clinical characteristics. Br J Haematol. 1993 Nov;85(3):504–513. doi: 10.1111/j.1365-2141.1993.tb03340.x. [DOI] [PubMed] [Google Scholar]
  25. Saleun J. P., Vicariot M., Deroff P., Morin J. F. Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol. 1982 Jan;35(1):63–68. doi: 10.1136/jcp.35.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. San Miguel J. F., Caballero M. D., Gonzalez M., Zola H., Lopez Borrasca A. Immunological phenotype of neoplasms involving the B cell in the last step of differentiation. Br J Haematol. 1986 Jan;62(1):75–83. doi: 10.1111/j.1365-2141.1986.tb02902.x. [DOI] [PubMed] [Google Scholar]
  27. San Miguel J. F., González M., Gascón A., Moro M. J., Hernández J. M., Ortega F., Jimenez R., Guerras L., Romero M., Casanova F. Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies. Br J Haematol. 1991 Feb;77(2):185–190. doi: 10.1111/j.1365-2141.1991.tb07975.x. [DOI] [PubMed] [Google Scholar]
  28. Shimazaki C., Fried J., Perez A. G., Scheinberg D. A., Atzpodien J., Wang C. Y., Wisniewolski R., Clarkson B. D. Immunophenotypic analysis of lymphocytes and myeloma cells in patients with multiple myeloma. Acta Haematol. 1990;83(3):123–129. doi: 10.1159/000205187. [DOI] [PubMed] [Google Scholar]
  29. Sonneveld P., Durie B. G., Lokhorst H. M., Frutiger Y., Schoester M., Vela E. E. Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Br J Haematol. 1993 Jan;83(1):63–67. doi: 10.1111/j.1365-2141.1993.tb04632.x. [DOI] [PubMed] [Google Scholar]
  30. Tazzari P. L., Gobbi M., Dinota A., Bontadini A., Grassi G., Cerato C., Cavo M., Pileri S., Caligaris-Cappio F., Tura S. Normal and neoplastic plasma cell membrane phenotype: studies with new monoclonal antibodies. Clin Exp Immunol. 1987 Oct;70(1):192–200. [PMC free article] [PubMed] [Google Scholar]
  31. Terstappen L. W., Johnsen S., Segers-Nolten I. M., Loken M. R. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry. Blood. 1990 Nov 1;76(9):1739–1747. [PubMed] [Google Scholar]
  32. Uckun F. M. Regulation of human B-cell ontogeny. Blood. 1990 Nov 15;76(10):1908–1923. [PubMed] [Google Scholar]
  33. Van Camp B., Durie B. G., Spier C., De Waele M., Van Riet I., Vela E., Frutiger Y., Richter L., Grogan T. M. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood. 1990 Jul 15;76(2):377–382. [PubMed] [Google Scholar]
  34. Van Riet I., De Waele M., Remels L., Lacor P., Schots R., Van Camp B. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br J Haematol. 1991 Nov;79(3):421–427. doi: 10.1111/j.1365-2141.1991.tb08050.x. [DOI] [PubMed] [Google Scholar]
  35. Zeleznik-Le N. J., Metzgar R. S. Expression of CD9 antigen on normal activated human B cells. Cell Immunol. 1989 Oct 1;123(1):70–82. doi: 10.1016/0008-8749(89)90269-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES